![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.413, 2003-01, pp. : 5-5
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
ACE inhibitors not worth it as first-line therapy in hypertension
Inpharma, Vol. 1, Iss. 1388, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Spironolactone "safer first-line" therapy for hypertension
Reactions Weekly, Vol. 1, Iss. 1254, 2009-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
-Blockers: "not appropriate" first-line therapy for hypertension
Inpharma, Vol. 1, Iss. 1417, 2003-01 ,pp. :